angiogenesis inhibitors
Trials Results

Aflibercept - Bevacizumab - Cediranib - Motesanib - Sorafenib - Vandetanib

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

advanced breast cancer (metastatic)

bevacizumab
Burstein, 2005bevacizumab + methotrexatemethotrexateNegative
AVF2119g (Miller) cape, 2005bevacizumab + capecitabinecapecitabine Risk of bias Suggesting
E2100 (Miller), 2007bevacizumab + taxanestaxanes Risk of bias SuggestingNCT00028990
AVADO (Miles) 15mg , 2009bevacizumab + docetaxeldocetaxelSuggesting
RIBBON-I (Robert) on top capecitabine, 2009bevacizumab + capecitabinecapecitabineSuggesting
RIBBON-I (Robert) on top Tax or anthra, 2009bevacizumab + taxanestaxanesSuggesting
RIBBON-2 (Brufsky), 2009bevacizumav + CTCT aloneSuggesting
AVADO (Miles) 7.5mg, 2010bevacizumab + docetaxeldocetaxelNegative
Martin bevacizumab, 2011bevacizumab + paclitaxelpaclitaxelNegative
ceritinib
Hyamscediranib + fulvestrantfulvestrant - NCT00454805
motesanib
Martin (motesanib), 2011motesanib + paclitaxelpaclitaxel - NCT00356681
sorafenib
Schwartzberg, 2013sorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone Exploratory SuggestingNCT00493636
Gradishar, 2013sorafenib + paclitaxelpaclitaxel alone Exploratory Negative
RESILIENCE, 2013 ongoing sorafenib + capecitabinecapecitabine alone -

lung cancer (metastatic)

aflibercept
Ramlau, 2012Aflibercept and Docetaxel Docetaxel -
bevacizumab
Johnson, 2004bevacizumabplatinum based CT -
Sandler, 2006bevacizumabplatinum based CT -
Herbst, 2007bevacizumabplatinum based CT -
Nishio, 2009bevacizumabplatinum based CT -
Reck, 2010bevacizumab -
Herbst, 2011bevacizumab + erlotiniberlotinib alone -
ceritinib
Goss, 2010cediranib carboplatin and paclitaxel -
Dy, 2013cediranib gemcitabine and carboplatin -
Laurie, 2014cediranib carboplatin and paclitaxel -
docetaxel
REVEL, 2014ramucirumab + docetaxeldocetaxel alone - NCT01168973
motesanib
Scagliottib MONET1, 2012motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013pazopanib pemetrexed -
sorafenib
Scagliotti, 2010sorafenibplacebo -
Spigel, 2011sorafenib and erlotinib erlotinib -
Wakelee, 2012sorafenib -
Paz-Ares, 2012sorafenib -
sunitinib
Scagliottia, 2012Sunitinib plus erlotinib erlotinib -
Groen, 2013sunitinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014sunitinib pemetrexed -
vandetanib
Heymach, 2007 vandetanib plus docetaxel placebo plus docetaxel -
Natale, 2009Vandetanib versus gefitinib -
Natale, 2011Vandetanib gefitinib -
de Boer, 2011Vandetanib plus pemetrexed -
Lee ZEPHYR, 2012Vandetanib placebo -
Ahn, 2013vandetanib maintenance -
Aisner, 2013vandetanib -

renal-cell carcinoma (advanced)

bevacizumab
Yang, 2003bevacizumabplacebo Exploratory -
AVOREN, 2007bevacizumab plus interferon alfainterferon alphaSuggesting
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphaSuggesting



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons